glp-1 drugs long term effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists Adverse Effects of GLP-1 Receptor
Description
Koch JM, Dashtipour K, Chen JJ
Announcing the preclinical milestone, Nimbus signaled that it was looking beyond cardiometabolic disorders, into weight loss and management: I look forward to continuing to apply Nimbus discovery engine to address targets across metabolic, cardiovascular, and obesity-related diseases, Peter J
These data align with an integrated analysis of 36 clinical studies that affirmed cardiovascular safety with up to 4-years treatment with either DPP-4 inhibitors or GLP-1R agonists [655]
The choice depends on medical advice, personal preference and how well the medication works for the individual
Overall, preceding or combining GLP1s with intensive behavioral therapy shows promise in increasing achieved weight reduction
